A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies

PharmacoEconomics

Volumn 24, Issue SUPPL. 1, 2006, Pages 5-19

  Bagust, Adrian ^a,g   Evans, Marc ^b   Beale, Sophie ^c   Home, Philip D ^d   Perry, Andrew S ^e   Stewart, Murray ^f  

^a UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e GLAXOSMITHKLINE   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

^g ULMS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA;

AGE DISTRIBUTION; BLOOD PRESSURE; BODY MASS; CALIBRATION; CLINICAL TRIAL; DATA ANALYSIS; DISEASE COURSE; ECONOMIC ASPECT; ETHNOLOGY; EVALUATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; STANDARDIZATION;

EID: 33645010723     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624001-00002     Document Type: Review

References (62)

1. Seed JC, Acton FS, Stunkard AJ. A model for the appraisal of glucose metabolism. Clin Pharm Therap 1962; 3: 191-215
2. Carson ER, Cobelli C, Finkelstein L, editors. Mathematical modeling of metabolic and endocrine systems. New York: Wiley and Sons; 1983
3. Summers RL, Montani J-P, Woodward LH, et al. Theoretical analysis of the mechanisms of chronic hyperinsulinaemia. Comput Biol Med 1997; 27: 249-56
4. DCCT Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996; 276: 1409-15
5. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997; 20: 725-34
6. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycaemia. Diabetes Care 1997; 20: 735-44
7. Brown JB, Russell A, Chan W, et al. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 2000; 50 Suppl 3: S15-S46
8. Palmer AJ, Brandt A, Gozzoli V, et al. Outline of a diabetes disease management model: principles and applications. Diabetes Res Clin Pract 2000; 50 Suppl 3: S47-S56
9. Clarke PM, Gray AM, Briggs A, et al. UK Prospective Diabetes (UKPDS) Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the UKPDS Outcomes Model (UKPDS no. 68). Diabetologia 2004; 47: 1747-59
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
11. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
12. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-12
13. Bagust A, Hopkinson PK, Maier W, Currie CJ. An economic model of the long-term health care burden of type II diabetes. Diabetologia 2001; 44: 2140-55
14. Haffner SM, Miettinen H, Stern MP. Are risk factors for conversion to NIDDM similar in high and low risk population? Diabetologia 1997; 40: 62-6
15. Skarfors ET, Selinus KI, Lithell HO. Risk factors for developing non-insulin dependent diabetes: a 10 year follow up of men in Uppsala. BMJ 1991; 303: 755-60
16. Hanley AJG, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease. The San Antonio Heart Study. Diabetes Care 2002; 25: 1177-84
17. Després JP, Lamarche B, Mauriège P, et al. Hyperinsulinaemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7
18. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycaemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989; 38: 387-95
19. Kahn SE. The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metabol 2001; 86: 4047-58
20. UK Prospective Diabetes Study Group. U.K prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58
21. Levy J, Atkinson AB, Bell PM, et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10 year follow-up of the Belfast Diet Study. Diabet Med 1998; 15: 290-6
22. Colman E, Katzel LI, Rogus E, et al. Weight loss reduces abdominal fat and improves insulin action in middle-aged and older men with impaired glucose tolerance. Metabolism 1995; 44: 1502-8
23. Weyer C, Hanson K, Bogardus C, et al. Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight. Diabetologia 2000; 43: 36-46
24. Banerji MA, Lebowitz J, Chaiken RL, et al. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects.Am J Physiol 1997; 273: E425-32
25. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321-6
26. Dixon JB, Dixon AF, O'Brien PE. Improvements in insulin sensitivity and beta-cell function (HOMA) with weight loss in the severely obese. Homeostatic model assessment. Diabet Med 2003; 20: 127-34
27. Evans LM, Khan N, Rees A. Diabetic dyslipidaemia and coronary heart disease: new perspectives. Curr Opin Lipidol 1999; 10: 387-91
28. Evans LM, Rees A. Diabetic dyslipidaemia. In: Gaw, A., Shepherd, J., editors. Lipids and atherosclerosis annual 2001. London: Dunitz M; 2001
29. Dixon JB, O'Brien PE. Lipid profile in the severely obese: changes with weight loss after lap-band surgery. Obes Res 2002; 10: 903-10
30. Carmena R, Ascaso JF, Real JT. Impact of obesity in primary hyperlipidaemias. Nutr Metab Cardiovasc Dis 2001; 11: 354-9
31. Dengel DR, Hagberg JM, Pratley RE, et al. Improvements in blood pressure, glucose metabolism and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middle-aged men. Metabol Clin Exp 1998; 47: 1075-82
32. Dawson KG, McKenzie JK, Ross SA, et al. Report of the Canadian Hypertension Society Consensus Conference: 5. Hypertension and diabetes. Can Med Assoc J 1993; 149: 821-6
33. Carroll MF, Izard A, Riboni K, et al. Fasting hyperglycaemia predicts the magnitude of postprandial hyperglycaemia. Diabetes Care 2002; 25: 1247-8
34. Levy JC, Matthews DR, Hermans MP. Correct Homeostasis Model Assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998; 21: 2191-2. Software version of the HOMA model may be downloaded from http://www.dtu.ox.ac. uk/homa/download.html
35. Hadden DR, Montgomery DAD, Skelly RJ, et al. Maturity onset diabetes: response to intensive dietary management. BMJ 1975; 3: 275-8
36. UKPDS Group. UK Prospective Diabetes Study: 7. Response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients. Metabolism 1990; 39: 905-12
37. Davis TME, Cull CA, Holman RR. Relationship between ethnicity and glycaemic control, lipid profiles and blood pressure during the first 9 years of type 2 diabetes (UKPDS 55). Diabetes Care 2001; 24: 1167-74
38. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
39. Tong PC, Lee ZS, Sei M-M, et al. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 2002; 162: 2428-35
40. Ferrier KE, Muhlmann MH, Baguet J-P, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020-5
41. Borghi C, Dormi A, Veronesi M, et al. Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J Clin Hypertens 2002; 4: 277-85
42. Sposito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin and pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83: 1497-1499, A8
43. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 2000; 34: 1281-6
44. Tonolo G, Melis MG, Formato M, et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30: 980-7
45. Beale S, Bagust A, Shearer A, et al. Cost-effectiveness of rosiglitazone combination for the treatment of type 2 diabetes in the UK. Pharmacoeconomics 2006; 24 (Suppl. 1): 21-34
46. Birkeland KI, Furuseth K, Melander A, et al. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Diabetes Care 1994; 17: 45-9
47. DeFronzo RA, Goodman AM. Multicenter Metformin Study group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 33: 541-9
48. Campbell IW, Menzies DG, Chalmers J, et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabet Metabol 1994; 21: 394-400
49. Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996; 19: 849-56
50. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-8
51. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea alone and in various combinations. Diabetes Care 1994; 17: 1100-9
52. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33
53. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103: 491-7
54. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000; 108 (6A): 16S-22S
55. Wolffenbuttel BHR, Sels J-P JE, Rondas-Colbers GJWM, Menheere P.P.C.A. Prognostic factors for successful insulin therapy in subjects with type 2 diabetes. Neth J Med 1999; 54: 63-9
56. Landstedt-Hallin L, Arner P, Lins P-E, et al. The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Diabet Med 1999; 16: 827-34
57. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001; 101: 671-9
58. Levien TL, Baker DE, Campbell RK, White JR Jr. Nateglinide therapy for type 2 diabetes mellitus. Ann Pharmacother 2001; 35: 1426-34
59. Bagust A, McEwan P. Guidelines for computer modelling of diabetes and its complications [Letter]. Diabetes Care 2005; 28: 50
60. Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems - the mathematical simulation. J Biomed Informatics 2002; 35: 37-50
61. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003; 26: 3093-101 and on-line appendix: http://care. diabetesjournals.org/content/vol26/issue11/images/data/3093/DC1/Online Appendixdc0249.doc
62. Eddy DM, Schlessinger L. Validation of archimedes diabetes model. Diabetes Care 2003; 26: 3102-10